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Introduction
experimental studies and clinical trials are ongoing in the 
search for an effective prevention or treatment of Alzhei-
mer’s disease (AD) [1–3]. These studies and trials often 
target the amyloid-beta peptide (Aβ), which plays a major 
role in AD pathogenesis [4]. effective drug develop-
ment has remained without success and this is thought to 
originate from the fact that Aβ can appear in many differ-
ent shapes that can interconvert within a dynamical inter-
play. This finding triggered a vast exploration of the many 
conformations the peptide can adopt, as well as the aim 
to precisely pinpoint which of these conformations can 
be claimed as “the toxic species”, such that specific drug 
targeting can be employed. To complicate matters even 
more, a heterogeneous pool of monomeric Aβ varying in 
length from 37 to 49 amino acids is produced by proteo-
lytic cleavage from the transmembrane amyloid precursor 
protein (APP) by β- and γ-secretases [5, 6] (Fig. 1). Most 
research effort has been focused on the most abundant form 
Aβ1−40, which comprises 40 amino acids. The longer and 
less abundant Aβ1−42, C-terminally extended by two resi-
dues, has been found to be more aggregation-prone [7]. 
Nonetheless, it has recently been discovered by us [8–10] 
and other groups [11–14] that the co-occurrence of pep-
tides varying in length can affect the neurotoxic and aggre-
gation potential of the total Aβ pool. It was also recognized 
that particularly small aggregated forms of Aβ are potently 
toxic, rather than the mature amyloid fibrils as observed in 
the brain of AD patients. Therefore, a lot of research has 
aimed at understanding the Aβ aggregation mechanism and 
identifying the intermediate species that occur along the 
aggregation pathway [15, 16]. The current amyloid cascade 
hypothesis suggests that AD-related synapto- and neurotox-
icity might be mediated by soluble Aβ oligomers [17, 18], 
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which have proven notoriously difficult to study in detail in 
vivo with the currently available technology. The dynam-
ics, stability, and transient lifetime of potentially toxic spe-
cies further hamper the possibility to precisely pinpoint 
the toxic structural aspects of Aβ aggregates. Moreover, 
the dynamic behavior of aggregation intermediates may 
actually provide an important source for toxicity of Aβ as 
isolated Aβ oligomers are only toxic in the presence of Aβ 
monomers that provide a source for continued growth of 
oligomers into fibrillar species [13, 19].
This review discusses how Aβ peptide dynamics can 
influence and contribute to Aβ-induced toxicity. Aβ dynam-
ics is mainly considered on two levels. First, we define 
intramolecular dynamics of Aβ as the intrinsic disorder or 
polypeptide backbone flexibility that is present in isolated 
Aβ monomeric peptides or aggregation states. Second, 
we define intermolecular dynamics as (1) the interplay 
between different Aβ alloforms present in the in vivo Aβ 
pool and (2) the dynamical equilibrium that exists between 
different Aβ species. with the term alloform, we refer to a 
distinct form of the Aβ peptide that is commonly treated as 
a single kind of peptide species, like Aβ length variants or 
side chain modifications. Finally, several external factors 
and interaction partners that can influence Aβ dynamics 
are addressed. The potential importance of Aβ dynamics in 
understanding AD pathology is highlighted with the aim of 
shaping new research orientations for AD treatment.
Intramolecular dynamics
The Aβ monomer has a high tendency to self-assemble into 
large aggregates and fibrils. It is increasingly recognized 
that despite the highly packed and ordered state of these 
higher-order aggregates, they often do contain a significant 
portion of flexible and intrinsically disordered regions [20]. 
The intrinsically disordered nature of the Aβ monomer is 
fairly well documented, but revealing the structural disor-
der in oligomers and fibrils has proven more challenging 
due to the difficulties in studying this phenomenon. In this 
section, we discuss the intrinsic structural disorder that is 
present in every Aβ aggregation state, and we illustrate how 
it contributes to Aβ-induced toxicity.
The intrinsically disordered Aβ monomer
Although the pathological hallmark of AD comprises 
insoluble Aβ deposits in neuritic plaques in the brain of AD 
patients, monomeric Aβ peptides have also been purified 
and characterized from brain tissue [21–24]. Size exclu-
sion chromatography (SeC) experiments suggested that 
the freshly dissolved peptide eluted as a single low molec-
ular weight species, consistent with a monomer or dimer 
[25–27]. These low molecular weight Aβ species were 
competent to deposit onto pre-existing amyloid in prepa-
rations of AD cortex, with a first-order kinetic dependence 
Fig. 1  Heterogeneity in the Aβ peptide pool. Sequential proteo-
lytic events by the β- and γ-secretase of the amyloid precursor pro-
tein (APP) give rise to the carboxy-terminal fragment (CTF), APP 
intracellular domain (AICD), and the amyloid-β peptide (Aβ). The 
heterogeneity in the Aβ pool originates from the proteolysis by the 
γ-secretase, but also post-translational modifications contribute to the 
formation of various Aβ alloforms. Mutations in Aβ and other exog-
enous factors can influence the dynamics that are observed within the 
Aβ system
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on soluble Aβ concentration [26]. Translational diffusion 
measurements by nuclear magnetic resonance (NMR) tech-
niques conclusively demonstrated that the form of the pep-
tide active in plaque deposition is a monomer [26]. Further 
NMR data revealed that monomeric Aβ exists in solution 
as disordered coils that lack regular α-helical or β-stranded 
structure [28–30]. Despite the challenging task because of 
its unstructured and amyloidogenic nature, the Aβ mono-
mer is now well recognized as an intrinsically disordered 
peptide (IDP). This implies that the monomeric Aβ peptide 
does not display a unique fold, as would be the case for a 
typical well-folded protein, but rather comprises a mix-
ture of rapidly interconverting conformations whereby the 
polypeptide backbone can sample the conformational space 
without any stable and well-defined conformational ensem-
ble (Fig. 2). Yet, it is possible to bias the ensemble toward 
distinct secondary structure elements by changing solution 
conditions and/or the oxidation state of Met35 [30–33].
Some experimental studies suggested that Aβ is not 
entirely a “random coil”. Ion mobility mass spectrometry 
(MS) combined with theoretical modeling showed that 
Aβ1−42 in aqueous solution adopts both extended chain as 
well as collapsed-coil structures [34]. Limited proteolysis 
successfully identified structured and disordered regions 
within Aβ [35]. This approach revealed a proteolytically 
resistant decapeptide, Ala21–Ala30, that was found in NMR 
studies to form a turn-like structure [30]. when the dynam-
ics of monomeric Aβ1−40 in solution was studied using 
15N-relaxation experiments, it revealed structural propen-
sities that correlate well with the secondary structure seg-
ments of the peptide that are present in the fibrils, and with 
the α-helical structure in membrane-mimicking systems 
[32, 36]. NMR studies further revealed subtle differences 
between Aβ1−40 and Aβ1−42 monomers whereby a modest 
increase in C-terminal rigidity has been observed in Aβ1−42 
versus Aβ1−40 [37]. various molecular dynamics simula-
tions also hinted that distinct intramolecular interaction pat-
terns occur in Aβ1−42 [28, 38, 39]. Such subtle differences 
between Aβ1−40 and Aβ1−42 were confirmed by molecular 
dynamics simulations [40, 41]. experimental results in 
combination with computational simulations have thus 
proven very powerful to shed light on the conformational 
landscape of IDPs. The emerging picture of Aβ comprises 
an IDP that can adapt a variety of collapsed and extended 
monomeric conformations and transiently samples long-
range intramolecular interactions without exclusively stabi-
lizing a specific globular fold.
even though the physiological function of Aβ remains 
obscure, the intrinsic structural flexibility offers certain 
advantages: high specificity and low affinity in the case of 
Fig. 2  various structures of Aβ that correspond to different experi-
mental conditions and phases in the aggregation landscape. a Four 
representatives of the structural ensemble of monomeric Aβ1−42 under 
aqueous conditions as derived from a combined molecular dynamics/
NMR approach [38]. extended as well as collapsed coil conforma-
tions with secondary structural elements can be observed. b Aβ1−40 
in presence of 50 mM NaCl at 15 °C [33] and Aβ1−42 in presence 
of 30 % hexafluoroisopropanol [32] contain an α-helical segment. c 
Fibril polymorphism illustrated by fibrillar Aβ1−42 [53], D23N Aβ1−40 
[74] and d the ultrastructure of Aβ1−40 [83], and brain-derived Aβ1−40 
[89]
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binding-induced folding IDPs (mostly exploited in signal-
ing pathways), and high binding promiscuity that is fre-
quently used by hub proteins in large interaction networks 
[42]. So its IDP nature facilitates the interaction of the pep-
tide with many different binding partners (see “Other play-
ers in the game”), including identical peptides and other Aβ 
alloforms. In addition, the high intramolecular flexibility of 
Aβ also simplifies post-translational modifications because 
the involved side chains are readily accessible (see “The in 
vivo Aβ pool: a cocktail of different interacting species”).
There is a well-established link between intrinsic poly-
peptide disorder and functional promiscuity. Protein moon-
lighting, the phenomenon of proteins exhibiting more than 
one unique biological function, is typically mediated by 
intrinsically disordered regions in polypeptides [43]. As 
IDPs can play a role in numerous biological processes, it 
is not surprising to find some of them involved in human 
diseases.
Intrinsic fibril flexibility can underlie disease progression 
and phenotype
Aβ fibrils contain high order and rigidity compared to Aβ 
monomers, but still retain a considerable amount of disor-
der in the N-terminal segment [44–47] and they are often 
polymorphous. The inherent disorder of Aβ fibrils and 
the associated fibril polymorphism could underlie time-
dependent structural changes during aging in AD and dif-
ferences in disease progression and phenotype.
The molecular dynamic nature of Aβ fibrils
even though the amyloid fibril state of Aβ has tradition-
ally been viewed as a rigid or semi-rigid state with the 
typical cross-β X-ray fiber diffraction pattern [48, 49], 
part of the peptide in this conformation is also flexible. 
This flexibility has been illustrated first by solid-state and 
solution NMR [50–54], electron paramagnetic resonance 
(ePR) [44], site-directed mutagenesis [55], limited pro-
teolysis and hydrogen-deuterium exchange (HDX) evalu-
ated by MS [45–47, 56], and even X-ray crystallography 
[57]. These studies suggested a hairpin-like arrangement 
of each Aβ monomer stacked within the fibril, consisting 
of two semi-rigidly organized β-strands linked by a flex-
ible connecting region (Fig. 2). The hydrophobic C-termi-
nus of Aβ1−42 in the fibril is highly resistant to HDX and 
forms the fibril core [53, 54]. In contrast, the C-terminus 
of Aβ1−40 in the fibril contains slightly more disorder [52, 
56, 58–61]. The N-terminal segment, which can range 
from 10 to 19 residues depending on the study, remains 
intrinsically disordered for both Aβ1−40 and Aβ1−42 fibrils 
(Table 1). This relatively hydrophilic part of the polypep-
tide chain is excluded from the H-bonded β-sheet fibril 
core and remains exposed to the solvent [44–47, 52–54, 
58–61]. Recently, differential scanning calorimetry sug-
gested that thermal denaturation of amyloid fibrils can take 
place and that this process can be considered as a revers-
ible equilibrium under certain experimental conditions, 
highlighting the dynamic nature of fibrils [62]. These 
Table 1  Secondary structure assignments of Aβ fibrils and structures deposited in the PDB
Fibril structures deposited in the PDB: synthetic Aβ1−40 (2LMN, 2LMO, 2LMP, 2LMQ), brain-derived Aβ1−40 (2M4J), synthetic D23N Aβ1−40 
(2LNQ), recombinant Aβ1−42 (2BeG)
Peptide Flexible regions (solvent-exposed) β-structured regions (non-exposed) Method References
Aβ1−40 N-terminus (Asp1-Phe19)
C-terminus (Met35-val40)


























Aβ1−40 Aβ1−42 N-terminus (Asp1-Tyr10)
C-terminus (val40-Ala42?)
Turn/bend? (Asp23-Gly29)
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observations illustrate the impact of the various dynamics 
within the Aβ system.
The inherent flexibility of Aβ fibrils also allows the 
internal fibril structure to evolve in time. Multidimensional 
infrared spectroscopy revealed that fresh and 4-year-old 
fibrils were structurally heterogeneous due to trapped water 
molecules that perturbed the H-bonding pattern in time 
[63]. Recently, Nilsson and coworkers [64] revealed con-
formational rearrangements during aging in plaques in the 
brains of AD mouse models using different luminescent 
conjugated polythiophenes.
Although ignored for a long time, structural disorder in 
fibrils seems to occur in various amyloidogenic proteins 
(e.g. α-synuclein, tau, and multiple prions) (reviewed in 
[20]). Structural disorder in fibrils has been suggested to 
stabilize fibril formation by accommodating destabilizing 
residues and by limiting the unfavorable entropy associated 
with the formation of the highly ordered cross-β spine.
Aβ fibrils are polymorphic entities
Overall fibril topology has been studied using cryo-electron 
microscopy and 3D reconstruction. In general, Aβ fibrils 
exhibit multiple distinct morphologies that can differ in 
fibril symmetry, width, twist period, and curvature [65, 
66]. This structural diversity is not limited to Aβ fibrils, but 
appears to be a fundamental property of the amyloid state 
[67–69]. Inter-sample polymorphism commonly occurs in 
vitro in different fibril growth conditions and is subject to 
pH, temperature, agitation, and salt conditions [70, 71]. A 
Darwinian-type “survival of the fittest” competition allows 
the type of fibril that is kinetically the most accessible in a 
given environment to be the most populated [72]. However, 
Aβ1−40 can also form at least 12 structurally distinct mor-
photypes under the same solution conditions (intra-sample 
polymorphism) indicating that this polymorphism arises 
from an intrinsic variability [73]. Interconversion between 
fibril polymorphs coexisting in solution can occur, result-
ing in the thermodynamically more stable polymorph, as 
was monitored by solid-state NMR over a period of several 
weeks for Aβ1−40 [74, 75].
Amyloid polymorphism can have several molecular ori-
gins that are not mutually exclusive [76–79]. First, mass-
per-length values obtained from scanning TeM indicate 
that fibrils can be composed of one to five protofilaments 
(the minimal fibrillar entities) [80, 81]. Second, distinct ori-
entations and modes of lateral association of protofilaments 
by different patterns of inter-residue interactions determine 
if protofilaments are oriented side-by-side [50, 82], offset 
from one another [76, 77], or winded around a hollow core 
[79]. Third, solid-state NMR demonstrated that agitated 
(striated) and quiescent (twisted) fibrils differ in the resi-
dues participating in the β-strands and such variations in 
the underlying protofilament substructure can contribute 
to polymorphism [59, 83]. Surprisingly, the Iowa mutant 
(D23N Aβ1−40) was recently found to form metastable 
fibrils with an antiparallel cross-β spine, indicating that a 
familial disease-related mutation can have profound effects 
on fibril structure [74]. Although the cross-β spine of Aβ 
fibers is a common feature, fibrils show a great variety of 
structural complexity that appears inherent to the dynamic 
nature of the peptide.
Fibril polymorphism could lead to different pathological 
outcomes
Fibrils can initiate inflammation in brain tissues and cell-
cultured microglia and astrocytes. Fibril-induced inflam-
mation then leads to the secretion of pro-inflammatory 
cytokines and the production of free radicals causing oxi-
dative damage [84, 85]. Substantial evidence provided that 
different fibril morphologies exert different toxicities in 
vitro, although toxic activity of oligomeric Aβ was reported 
to exceed that of the fibrillar form multiple times [53, 
59, 86–88]. For example, oligomeric Aβ correlated more 
strongly to cognitive impairment as compared to fibrillar 
Aβ of amyloid plaques [86, 87].
Fibril polymorphism could explain the weak correlation 
between plaque load and cognitive impairment. If plaques 
are comprised of different fibril polymorphs, different 
levels of toxicity could be associated to these amyloid 
deposits. In this case, the structural diversity of fibrils may 
account for differences in disease progression and pheno-
type as has been suggested by Tycko and coworkers [89]. 
They reported that Aβ fibrils seeded from human brain 
extracts differed between patients with different clinical 
history and neuropathology [89]. Moreover, fibril polymor-
phism has been linked previously to different phenotypes 
for hereditary transthyretin amyloidosis [90]. In this regard, 
the different architectures of wild-type Aβ and Iowa D23N 
fibrils, comprising respectively parallel and antiparallel 
β-sheet orientations, could underlie the different pathologi-
cal outcomes: sporadic AD versus early onset AD associ-
ated with cerebral amyloid angiopathy (CAA).
Aβ oligomers: a mishmash of conformations and sizes
Since the Aβ plaque load and AD severity could not be cor-
related [86, 87], growing evidence has revealed that soluble 
oligomers, either on- or off-pathway to fibrils (see “The in 
vivo Aβ pool: a cocktail of different interacting species”), 
play a primary role in AD. Soluble oligomers have com-
monly been associated with disease severity, the loss of 
synapses and neuronal damage (reviewed in [18]). The 
low abundance, heterogeneity, low solubility, and transient 
nature of Aβ oligomers have hindered structural studies. It 
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now becomes clear that Aβ oligomers exist in a broad range 
of interconverting assemblies varying in size, conforma-
tion, and associated toxicity (reviewed in [91, 92]).
Aβ oligomers can cause toxicity by a variety of mecha-
nisms (reviewed in [93]). To enable drug design, it is essen-
tial to establish the key determinants of oligomer toxicity. 
Several studies report that neurotoxic activity varies with 
Aβ oligomer size with small oligomers (n < 14) being most 
toxic [94, 95]. However, oligomer size is not sufficient to 
define toxicity as Aβ oligomers with similar size have been 
shown to exert different toxicities [96–98]. The underlying 
peptide conformation also needs to be taken into account as 
the interplay between Aβ oligomer size and conformation 
plays an important role in toxicity (reviewed in [92]). The 
design of a well-controlled study to investigate size and 
conformational impact on toxicity is notoriously difficult as 
different oligomer conformations and sizes are in continu-
ous exchange. However, studies in which different confor-
mations or sizes have been enriched or stabilized by means 
of crosslinking have been performed and careful conclu-
sions can be drawn from such studies. For example, differ-
ent Aβ oligomer conformations have been shown to induce 
neurotoxicity by distinct mechanisms in human cortical 
neurons [99]. One possibility to classify oligomers accord-
ing to their underlying structure is based on recognition by 
conformation-dependent antibodies [100–103]. Surpris-
ingly, soluble oligomers of a wide variety of amyloidogenic 
polypeptides (Aβ, α-synuclein, islet amyloid polypeptide, 
polyglutamine, lysozyme, human insulin and prion peptide) 
react with the oligomer-specific A11 antibody developed in 
the laboratory of Charles Glabe, suggesting that there has 
to be a common denominator to their toxic origin. Inter-
estingly, pre-incubation of mouse hippocampal neurons 
with the A11 antibody, before treatment with Aβ, rescues 
them from the neurotoxic effects induced by Aβ [8]. It has 
been suggested that A11 positive oligomers are composed 
of antiparallel β-sheets, based on Fourier transform infra-
red (FTIR) spectroscopy. This antiparallel signature might 
represent a critical step in perturbation or permeabiliza-
tion of cell membranes leading to cell toxicity [104]. Later 
studies using FTIR, ePR, and X-ray crystallography have 
confirmed that oligomeric species can be characterized by 
an antiparallel β-sheet orientation, while most fibrils con-
sist of in-register, parallel β-sheets [105–109]. Moreover, 
antiparallel oligomers displayed a lower content in second-
ary structure and faster HDX kinetics compared to fibrils, 
suggesting a higher intrinsic flexibility [104].
Apart from size and peptide conformation, this intrinsic 
flexibility of the Aβ oligomer can also be a key determinant 
of Aβ-induced toxicity. Several studies have shown that the 
N-terminus retains a degree of flexibility upon oligomeriza-
tion and is exposed to the solvent [41, 109–111]. Ahmed 
and coworkers reported solution NMR measurements of 
Aβ1−42 pentamers [111]. The authors found that the loosely 
packed N-terminal segment of Aβ was defined by HDX 
ratios approaching 1 for residues Asp1-Gly9, indicating 
high solvent accessibility and nearly complete exchange 
within the acquisition time (<1.5 h). In contrast, val40-Ala42 
were less solvent accessible and most likely buried within 
the center of the oligomer. Similar results were obtained for 
packing of the Aβ peptide within Aβ1−42 dodecamers. Site-
directed spin labeling of Aβ1−42 combined with ePR spec-
troscopy showed that the N-terminus was loosely packed 
within the dodecamer, while residues Ile32-val40 formed a 
tight core [109]. Increased structural disorder and solvent 
exposure of hydrophobic segments of the oligomer have 
been suggested to be a common feature of highly toxic, 
soluble aggregates [96–98, 112]. Recent work has shown 
that the most cytotoxic, oligomeric species of the e22G 
(arctic) variant of Aβ1−42 interacted more strongly with 
1-anilinoaphthalene 8-sulfonate (ANS), a dye sensitive to 
exposed hydrophobic patches [112]. A higher degree of 
solvent-exposed, hydrophobic regions was further shown to 
lead to a disturbed cellular calcium homeostasis, likely due 
to disruption of the cell membrane [98]. Moreover, oligom-
ers have been shown to bind with higher affinity and cause 
more disruption of synthetic membranes as compared to 
the higher-ordered fibrils [113]. These data emphasize the 
importance of intrinsic disorder and molecular flexibility of 
Aβ oligomers for the toxicity mechanism.
In conclusion, a re-evaluation of the oligomer cascade 
hypothesis is needed (reviewed in [114]). whereas ear-
lier hypotheses held one single oligomer of a predefined 
size responsible for toxicity [23, 115], it is obvious that a 
diverse “Aβ oligomeric soup” exists, consisting of a large 
variety of rapidly exchangeable polymorphs that differ 
in size, conformation, hydrophobicity, solvent exposure, 
intrinsic disorder (or internal flexibility), and toxicity. The 
oligomer cascade hypothesis should take into account that 
it is likely that the entire dynamic Aβ oligomeric soup con-
tributes to the heterogeneity of AD progression and pheno-
type, via various toxic mechanisms.
Intermolecular dynamics
As the in vivo Aβ pool is a mix of species influencing one 
another, one must also consider the dynamics between 
different Aβ species when regarding Aβ-related toxicity. 
First, Aβ peptides of various lengths are produced due to 
the heterogeneous cleavage pattern of APP by γ-secretase 
[5, 6]. This gives rise to the production of Aβ1−40, smaller 
amounts of Aβ1−42, and trace amounts of peptides ranging 
in length from 37 to 49 amino acids [116–118]. Second, a 
dynamical equilibrium exists between different aggregation 
states during Aβ aggregation. Studying the behavior of Aβ 
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peptide mixtures and revealing the dynamics of intercon-
version among different aggregate species will be crucial in 
understanding the AD-related toxic effects of Aβ.
The in vivo Aβ pool: a cocktail of different interacting 
species
The large majority of biophysical and cell biological stud-
ies investigating the role of Aβ in AD have focused either 
on pure Aβ1−40 or on pure Aβ1−42, the two predominant 
Aβ alloforms present in the brain [7, 119]. The in vivo Aβ 
pool not only contains different Aβ peptide lengths but also 
comprises post-translationally modified Aβ [120] (Fig. 1). 
Aβ peptides can undergo racemization [121, 122], isomeri-
zation [123], phosphorylation [124, 125], oxidation [126, 
127], non-enzymatic glycation [128], and pyroglutamyla-
tion [129]. Post-translational oxidation of Met35 affects 
fibril flexibility within Aβ plaques [127]. Met35 oxidation 
also has been shown to impede the rate of Aβ aggregation 
in vitro [30], possibly by decreasing the β-strand content 
of the C-terminal region [130]. Furthermore, proteins can 
become modified by non-enzymatic glycation upon aging. 
Advanced glycation end products (AGes), found in Aβ 
plaques and in neurons, and their receptor RAGe play an 
important role in AD by contributing to oxidative stress and 
by triggering inflammation signaling pathways [128, 131, 
132]. For other modifications, it remains largely unknown 
how they can affect Aβ aggregation dynamics.
various forms of Aβ co-exist and co-deposit in amy-
loid fibrils and plaques [23, 128]. It has become clear that 
biologically relevant mixtures of Aβ alloforms behave in 
a more complex manner in vitro than anticipated from 
their behavior in isolation, in terms of aggregation proper-
ties and toxicity [8–12]. For example, Aβ1−38 and Aβ1−40 
exerted little toxicity in isolation, but were highly toxic 
to a neuroblastoma cell line when tested in a mixture, 
whereas addition of Aβ1−38 to Aβ1−42 had a protective 
effect [10].
Recently, it has been demonstrated that minor shifts in 
the Aβ1−42:Aβ1−40 ratio can modulate neurotoxicity [8]. 
The aggregation of samples of Aβ lengths in various com-
positions were monitored by NMR allowing simultaneous 
investigation of both Aβ1−42 and Aβ1−40 in the same sam-
ple by combining 15N-isotope-labeling of one Aβ alloform 
with 15N-edited filter experiments [9]. It was revealed that 
Aβ1−42 and Aβ1−40 directly interact and influence oligomer 
formation and aggregation kinetics. Moreover, cross-seed-
ing data revealed structural differences between the dif-
ferent ratios at the level of the oligomeric state. A subtle 
change in the Aβ1−42:Aβ1−40 ratio was suggested to induce 
differences in conformational plasticity of the oligomeric 
peptide mixtures [9]. High molecular weight (HMw) 
mass spectra further showed that a continuous range of 
oligomeric intermediates were formed upon incubation of 
Aβ through a monomer addition process for the time frame 
within which toxicity exists [8, 9]. This observation is in 
agreement with the “coalescence and reorganization model 
of amyloid formation” [133], but also with the principle of 
a template-dependent dock-and-lock-and-block mechanism 
whereby the locking of a peptide cannot efficiently occur 
unless the previously loaded peptide has assembled into 
the correct position [134]. This can be envisaged in the fol-
lowing way: intrinsically disordered Aβ monomers diffuse 
freely and can attach individually to each other, to a pre-
existing oligomer or to the fiber surface, especially through 
the distal ends. The crucial step occurs when the incoming 
monomer collides with the docking surface. In the case of 
a productive association, a permanent attachment can then 
take place, perhaps accompanied by a minor structural rear-
rangement. The conformational constraints of the mono-
mers will therefore influence the efficiency and kinetics 
of the aggregation as well as the architecture of Aβ fibrils 
[135] (see “Aβ fibrils are polymorphic entities”). Alloform 
differences of the monomeric conformation are essential at 
this point to interpret productive or non-productive inter-
actions [38, 40, 41], particularly in the complex in vivo 
pool of peptides. Aβ1−42 has the tendency to sample more 
fibril-like conformations compared to Aβ1−40 and as such 
can simply dock to fibril-like oligomers leading to highly 
productive (on-pathway) interactions. The more rigid and 
less flexible C-terminus of Aβ1−42 was suggested to enable 
the formation of a larger number of intramolecular contacts 
than Aβ1−40 [37, 40] and therefore provide a more exten-
sive hydrophobic surface for intermolecular interactions. 
experiments using amino acid substitutions in the C-ter-
minal part of Aβ1−40 and Aβ1−42 confirmed that (i) the sta-
bility of the β-hairpin structure was increased by reducing 
the backbone flexibility and strengthening the hydrophobic 
interactions between the putative β-strands, (ii) destabiliz-
ing mutations in the C-terminal part of Aβ1−42 lead to a 
more Aβ1−40-like behavior, and (iii) stabilizing mutations 
in the C-terminus of Aβ1−40 lead to a more Aβ1−42-like 
behavior [143]. The conformational search of the incom-
ing peptide for binding on the docking surface and for the 
proper orientation to lock-in-place could explain the com-
plex aggregation behavior of Aβ alloform mixtures. The 
balance between productive and non-productive interac-
tions in the transient encounter states is essential to guide 
the kinetics of aggregation, which in turn will define the 
time window within which the toxic species exist. Now that 
it becomes evident from independent research groups that 
the pattern of oligomer formation is mainly influenced by 
(patho)physiologically relevant Aβ1−42:Aβ1−40 ratios [136], 
it is also important to realize that independent (on- and 
off-) pathways exist for oligomerization and fibrillization 
of Aβ [137, 138].
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experimental approaches to obtain insight into complex Aβ 
dynamics
It seems logical that the assembly and disassembly of toxic 
species is a dynamic and continuous process, at least in 
the initial stages, that is directed by the Aβ pool composi-
tion. However, the possibility that toxicity is present over 
a series of conformers or sizes should not be disregarded 
[91, 92, 94, 139, 140]. The question is thus how biophysi-
cal parameters influence this process in vivo and affect the 
relative distribution of Aβ species over toxic and non-toxic 
conformations over time. Given the complexity of the bio-
physical environment in which Aβ aggregation occurs in 
vivo, such a question is extremely difficult to address. Nev-
ertheless, it is possible to analyze the dynamic features of 
this process in simplified and controlled conditions in vitro, 
and to evaluate the effect of the relative concentrations of 
Aβ1−40 and Aβ1−42 (and other alloforms) to the generation 
of neurotoxic species over time.
The combination of high-resolution NMR and HMw 
MS is perfectly suited to investigate the individual aggre-
gation behavior of the diverse Aβ alloforms in complex 
and heterogeneous sample compositions. This can yield a 
comprehensive aggregation fingerprint that allows us to 
understand how the different compositions of the Aβ pep-
tide pool influence the overall aggregation behavior. This 
aggregation fingerprint can be related to cytotoxicity, mem-
brane integrity, apoptotic responses, and functional read-
outs such as microelectrode arrays (MeA), in which syn-
aptic activities at different timeframes and under various 
conditions are monitored in response to Aβ [8, 141]. Such 
a fingerprint also opens perspectives to the diagnostics and 
therapeutics field when it can be correlated to biomarkers. 
Patient-specific treatment (personalized medicine) could be 
based on the detailed characterization of the composition 
of the Aβ pool. It will be essential to correlate the aggre-
gation fingerprint of such compositions with disease sever-
ity and the (ir)reversibility of the disease “progress”. It is 
also important to cover the overall dynamics in these pools 
rather than focusing on particular “toxic” intermediates 
that are only transient in the aggregation process. This will 
allow tackling the source of toxicity and limiting the time 
frame in which the toxic assemblies can exist. Aggregation 
fingerprints will thus be essential to better understand the 
Aβ-induced pathogenesis of AD and the biophysical pro-
cesses that underlie the cell biological responses.
The interaction between different species present 
during Aβ aggregation
NMR relaxation measurements showed that monomers are 
constantly binding to and being released from oligomers 
in vitro [142, 143]. estimates showed that approximately 
3 % of the peptide within the oligomer undergoes exchange 
with free monomer in pseudo-equilibrium conditions, sug-
gesting that exchange occurs predominantly from the oli-
gomer surface. A large part of the hydrophobic C-terminal 
region is involved in the association of monomer onto 
the oligomer surface [142]. In a next aggregation phase, 
protofibrils are formed that are also in constant exchange 
with monomers through the same surface region [144]. An 
elegant combination of 19F-NMR and other biophysical 
techniques revealed a heterogeneous mixture of small Aβ 
oligomers that exist in pseudo-equilibrium with protofibrils 
and fibrils during the early stages of aggregation [145].
Protofibrils self-associate and give rise to mature fibrils 
that can thermodynamically be considered as the most sta-
ble aggregation state due to the high density of intermolec-
ular hydrogen bonding and steric zipper interactions [146]. 
However, fibrils are not static and irreversible end species, 
as was the traditional view, but were shown to continuously 
dissociate and reassociate through both fibril ends [147]. 
Aβ1−40 fibrils recycle to a greater extent than Aβ1−42 fibrils, 
which could be attributed to a difference in fibril dissolu-
tion rate. These findings are consistent with a dynamical 
model for interpreting plaque morphology, in which aggre-
gation and disaggregation were proposed to be in steady-
state equilibrium [148]. The species involved in the fibril 
recycling process are still a matter of debate. Differential 
solution NMR isotope labeling experiments revealed that 
Aβ1−40 monomers can replace Aβ1−42 on Aβ1−42 aggre-
gates, recycling Aβ1−42 monomers back into solution [14]. 
Later reports confirmed the constant recycling of Aβ1−40 
and Aβ1−42 monomers and competition of binding for the 
ends of protofibrillar and fibrillar aggregates [13]. Alter-
natively, the accumulation of fibrils could be associated 
with the generation of diffusible lower molecular weight 
aggregates. This idea is consistent with the observation of 
a halo of oligomeric Aβ surrounding senile plaques when 
analyzed by array tomography [149]. Recently, Knowles 
and coworkers demonstrated that the secondary nucleation 
pathway can be a major source of oligomers once the criti-
cal concentration of amyloid fibrils (in the order of 10 nM) 
has formed [150]. Hereby, the surfaces of existing fibrils 
catalyze the nucleation of new aggregates from the mono-
meric state, with a rate dependent on both the concentration 
of the monomers and that of the existing fibrils. As the crit-
ical fibril concentration is lower than the aggregate loads 
present in brains of AD patients, this pathway is likely to be 
active in the brain [150].
The dynamical equilibrium potentially contributes 
to Aβ-associated toxicity
The co-existence of different Aβ aggregate species should 
be taken into account when analyzing Aβ toxicity studies. 
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For example, fibrils act as a reservoir of soluble aggregates 
that can diffuse and induce toxic effects. The halo of oli-
gomers surrounding senile plaques co-localizes with loss of 
excitatory synapses and spine collapse [149] and the disrup-
tion of dendritic spines in the vicinity of plaques is depend-
ent on their distance from these plaques [151]. Moreover, 
fibrils can be destabilized by brain lipids and reverted into 
neurotoxic soluble protofibrils [139]. Amyloid fibrils can 
thus be toxic per se (see “Fibril polymorphism could lead 
to different pathological outcomes”) or can function as a 
potential source of neurotoxic oligomeric species [152, 
153]. It has also been suggested that the ongoing polym-
erization process, rather than the formation of one stable 
aggregate, is responsible for Aβ-related toxicity [19, 154]. 
In accordance with this hypothesis, crude Aβ1−42 prepara-
tions containing a monomeric and heterogeneous mixture 
of Aβ1−42 oligomers and protofibrils were more toxic than 
purified monomeric, protofibrillar fractions or fibrils. The 
toxicity of protofibrils was directly linked with their inter-
actions with monomeric Aβ1−42 and strongly dependent on 
their ability to convert into fibrils. Moreover, the ongoing 
Aβ aggregation process, rather than distinct aggregation 
states, elicited alterations in astrocyte metabolic pheno-
types [19]. Therefore, insight into the dynamic equilibrium 
is required to fully understand Aβ toxicity.
Other players in the game
The modulation of Aβ production, aggregation, and deg-
radation by environmental factors [155–157], genetic risk 
factors [158–161], post-translational modifications [127], 
and an individual’s lifestyle [162–169] has been exten-
sively reviewed before and does not lie in the scope of this 
review. Only a few reports discuss the influence of these 
factors on Aβ dynamics.
Metals have been shown to affect Aβ intramolecular 
dynamics. Binding of zinc to the N-terminus of the Aβ 
monomer leads to a decrease in the intrinsic mobility of 
this region and the formation of a turn-like conformation 
in residues val24-Lys28 promoting aggregation, as shown 
by 15N relaxation measurements [170]. Copper can also 
bind to the N-terminus, causing a structural ordering in this 
region [171], but slowing down aggregation [110].
There is evidence that membrane composition and prop-
erties, in turn, play a critical role in Aβ cytotoxicity asso-
ciated with its conformational changes and aggregation 
into oligomers and fibrils ([172–174], reviewed in [175]). 
Moreover, interaction with lipid membranes can modu-
late Aβ peptide conformation and aggregation properties 
(reviewed in [175, 176]).
Genetic evidence suggested a role for chaperones in AD 
[177] and abundant chaperone levels block formation of 
Aβ aggregates as was demonstrated in a Caenorhabditis 
elegans disease model [178]. In vitro results indicated a 
role for heat shock proteins in the early aggregation events 
by interfering with the dynamical aggregation process 
[179]. The BRICHOS domain, a chaperone-like domain 
found in lung surfactant protein C, is reported to be a 
potent in vitro inhibitor of Aβ aggregation [180]. The con-
tribution of chaperones in the context of AD is reviewed in 
[181].
Interactions of Aβ with small molecules designed to 
target Aβ toxicity and/or Aβ aggregation have also been 
extensively studied. These ligands are not only interest-
ing in light of drug development, but also provide a tool 
for addressing the modulation of Aβ dynamics upon ligand 
interaction [182–184].
As the Aβ monomer concentration affects the dynami-
cal equilibrium between monomers, oligomers, protofi-
brils, and fibrillar Aβ, it is also worthwhile to consider fac-
tors that modulate Aβ metabolism. Aluminium is known 
to increase the Aβ brain burden in experimental animals 
and this might be due to a direct influence upon Aβ anabo-
lism or to direct or indirect effects on Aβ catabolism [185]. 
Holtzman and coworkers reported that human cerebrospi-
nal fluid Aβ levels undergo diurnal fluctuations and that 
this cycle is disturbed following plaque formation before 
the appearance of any cognitive symptoms [186]. Aβ fluc-
tuations were affected by perturbation of the orexin signal-
ing pathway and the sleep-wake cycle and this suggested 
that sleep abnormalities in earlier life might predispose an 
individual to AD [187]. Cholesterol has been suggested 
to provide stability to membrane-adjacent lipid rafts and 
therefore facilitate the Aβ cleavage from APP [168]. Recent 
evidence showed that the γ-secretase subunit composition 
defines the Aβ profile and affects the ratio between allo-
forms [6]. This implies that external factors influencing the 
γ-secretase subunit composition will have a profound effect 
on Aβ toxicity.
Conclusions
Understanding the intrinsic molecular flexibility, dynamics 
of interactions, and the structural behavior of the various 
Aβ peptides is crucial to comprehend the molecular mecha-
nisms underlying the pathophysiology of Alzheimer’s dis-
ease. This will allow a more rational design of therapeu-
tic intervention strategies to halt the disease progress and 
neutralize the malignant action of Aβ aggregation. To gain 
understanding of these events is difficult if not impossi-
ble to follow in real-time in the human brain. Therefore, 
these events are often mimicked in the test tube in research 
laboratories where information on Aβ behavior can be fol-
lowed in molecular detail using advanced biophysical and 
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biochemical assays in the course of seconds to hours or 
days, which happen in patients over a range of years.
The intrinsically disordered nature of Aβ raises the ques-
tion of whether this peptide may act as signaling peptide, 
which is known to require a high degree of flexibility. It is 
striking to observe that many proteins involved in human 
diseases are in fact classified as IDPs (alpha-synuclein, 
tau, multiple prions) [188, 189]. This raises the question 
as to whether protein flexibility may act as a disease-con-
tributing factor as opposed to the generally accepted idea 
that specific sizes or conformations of oligomeric forms of 
these peptides induce pathogenesis. In this review we state 
that different types of dynamics can be distinguished vary-
ing from inter- to intramolecular factors as well as external 
factors and that recent observations strongly indicate that 
indeed the contribution of dynamics to pathogenesis war-
rants further investigation. As the dynamic nature of Aβ and 
its ability to undergo conformational changes and aggrega-
tion has hampered its study, promising new experimental 
approaches and chemical tools [182] are being developed 
to address Aβ dynamics, having the major advantage that 
they can be used directly without the need for modification 
of Aβ with additional amino acids or fluorophores [110, 
190]. while a lot has been learned in the past from the 
behavior of the Aβ system, it is clear that the picture is still 
incomplete and extremely complex. variability in terms of 
space (intra- and extracellular space, brain compartments, 
patient-to-patient differences, etc.) and time (circadian 
rhythm, aging, lifestyle, etc.) imposes additional dynami-
cal factors, emphasizing the importance to better under-
stand the fluctuating microenvironment. Therefore, it is 
opportune to compare the Aβ system to a complex ecosys-
tem or society, where minor perturbations might have pro-
found effects that can result in cataclysmic events. various 
Aβ alloforms interact and mutually influence each other’s 
behavior, but they also interact with the complex biological 
cell surface where they might exert a toxic effect by inter-
fering with its normal functionality. Therefore, a holistic 
view of the dynamical Aβ ecosystem would enable us to 
initiate a successful ecosystem management strategy to pre-
vent or remediate the AD pathobiology.
we summarized the evidence supporting the role of 
structural flexibility and in particular of the intrinsic pro-
tein disorder in the Aβ system to AD pathogenesis. A more 
systematic approach to the study of molecular flexibility in 
the Aβ system is required. This knowledge should then be 
integrated into future research efforts to optimize the clini-
cal outcomes of drug trials.
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